Emerging role of redox dysregulation in alcoholic and nonalcoholic fatty liver disease

Antioxidants and Redox Signaling

Volumn 15, Issue 2, 2011, Pages 421-424

  Feldstein, Ariel E ^a   Bailey, Shannon M ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE;

ALCOHOL CONSUMPTION; ALCOHOLIC FATTY LIVER; CELL ORGANELLE; CYTOKINE RELEASE; DISEASE COURSE; ENDOPLASMIC RETICULUM; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION; HUMAN; INFLAMMATION; INNATE IMMUNITY; INSULIN RESISTANCE; LIPID DIET; MITOCHONDRION; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ADIPOKINES; ANIMALS; DIETARY FATS; DISEASE MODELS, ANIMAL; ENDOPLASMIC RETICULUM; ETHANOL; FATTY LIVER; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; MITOCHONDRIA, LIVER; PROTEIN DENATURATION; RECEPTORS, ADIPONECTIN; SIGNAL TRANSDUCTION; SIRTUIN 1;

RODENTIA;

EID: 79959501180     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2011.3897     Document Type: Review

References (25)

1. Ajmo JM, Liang X, Rogers CQ, Pennock B, and You M. Resveratrol alleviates alcoholic fatty liver in mice. Am J Physiol Gastrointest Liver Physiol 295: G833-G842, 2008.
2. Bailey SM, Mantena SK, Millender-Swain T, Cakir Y, Jhala NC, Chhieng D, Pinkerton KE, and Ballinger SW. Ethanol and tobacco smoke increase hepatic steatosis and hypoxia in the hypercholesterolemic apoE-/- mouse: implications for a "multi-hit" hypothesis of fatty liver disease. Free Radic Biol Med 46: 928-938, 2009.
3. Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 7: 195-203, 2010.
4. Cohen JI, Chen X, and Nagy LE. Redox signaling and the innate immune system in alcoholic liver disease. Antioxid Redox Signal 15: 523-534, 2011.
5. Day CP. Genes or environment to determine alcoholic liver disease and non-alcoholic fatty liver disease. Liver Int 26: 1021-1028, 2006. (Pubitemid 44541742)
6. Eccleston HB, Andringa KK, Betancourt AM, King AL, Mantena SK, Swain TM, Tinsley HN, Nolte RN, Nagy TR, Abrams GA, and Bailey SM. Chronic exposure to a high-fat diet induces hepatic steatosis, impairs nitric oxide bioavailability, and modifies the mitochondrial proteome in mice. Antioxid Redox Signal 15: 447-459, 2011.
7. Feldstein AE. Novel insights into the pathophysiology of nonalcoholic fatty liver disease. Semin Liver Dis 30: 391-401, 2010.
8. Gentile CL, Frye M, and Pagliassotti MJ. Endoplasmic reticulum stress and the unfolded protein response in nonalcoholic fatty liver disease. Antioxid Redox Signal 15: 505-521, 2011.
9. Gornicka A, Morris-Stiff G, Thapaliya S, Papouchado BG, Berk M, and Feldstein AE. Transcriptional profile of genes involved in oxidative stress and antioxidant defense in a dietary murine model of steatohepatitis. Antioxid Redox Signal 15: 437-445, 2011.
10. Kapoor A and Sanyal AJ. Endoplasmic reticulum stress and the unfolded protein response. Clin Liver Dis 13: 581-590, 2009.
11. Liang X, Hu M, Rogers CQ, Shen Z, and You M. Role of SIRT1-FoxO1 signaling in dietary saturated fat-dependent upregulation of liver adiponectin receptor 2 in ethanol-administered mice. Antioxid Redox Signal 15: 425-435, 2011.
12. Loomba R, Sirlin CB, Schwimmer JB, and Lavine JE. Advances in pediatric nonalcoholic fatty liver disease. Hepatology 50: 1282-1293, 2009.
13. Ludwig J, Viggiano TR, McGill DB, and Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55: 434-438, 1980. (Pubitemid 10057164)
14. Maher JJ. New insights from rodent models of fatty liver disease. Antioxid Redox Signal 15: 535-550, 2011.
15. Mantena SK, King AL, Andringa KK, Eccleston HB, and Bailey SM. Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseases. Free Radic Biol Med 44: 1259-1272, 2008.
16. Mantena SK, King AL, Andringa KK, Landar A, Darley-Usmar V, and Bailey SM. Novel interactions of mitochondria and reactive oxygen/nitrogen species in alcohol mediated liver diseases. World J Gastroenterol 13: 4967-4973, 2007. (Pubitemid 47496829)
17. Marrero JA, Fontana RJ, Fu S, Conjeevaram HS, Su GL, and Lok AS. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol 42: 218-224, 2005. (Pubitemid 40143468)
18. Minino AM, Heron MP, and Smith BL. Deaths: preliminary data for 2004. Natl Vital Stat Rep 54: 1-49, 2006.
19. Morris EM, Rector RS, Thyfault JP, and Ibdah JA. Mitochondria and redox signaling in steatohepatitis. Antioxid Redox Signal 15: 485-504, 2011.
20. Neuschwander-Tetri BA and Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 37: 1202-1219, 2003. (Pubitemid 36538699)
21. Parola M and Marra F. Adipokines and redox signaling: impact on fatty liver disease. Antioxid Redox Signal 15: 461-483, 2011.
22. Pessayre D. Role of mitochondria in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 22 Suppl 1: S20-S27, 2007. (Pubitemid 46848985)
23. Ronis MJ, Wands JR, Badger TM, de la Monte SM, Lang CH, and Calissendorff J. Alcohol-induced disruption of endocrine signaling. Alcohol Clin Exp Res 31: 1269-1285, 2007. (Pubitemid 47063129)
24. Ruhl CE and Everhart JE. Epidemiology of nonalcoholic fatty liver. Clin Liver Dis 8: 501-519, vii, 2004. (Pubitemid 39141139)
25. Tsukamoto H, Machida K, Dynnyk A, and Mkrtchyan H. "Second hit" models of alcoholic liver disease. Semin Liver Dis 29: 178-187, 2009.